Vantage logo

A ternary outcome for Tocagen

Tocagen’s Toca-5 trial has survived two interim reviews, and faces final readout by the end of this year.

Vantage logo

Six burning Otezla questions

Planned divestment of Celgene’s psoriasis blockbuster means instant cashback for Bristol, a result the markets see as a win-win-win.

Vantage logo

Neptune leaves Astra at sea

The Neptune lung cancer study fails, denting yet further Astrazeneca and Bristol-Myers Squibb’s chances of challenging Merck & Co’s Keytruda on the basis of tumour…

Vantage logo

Zepsyre has a path to market at last

Pharmamar says the US FDA has given an accelerated approval filing plan its blessing, and that means a regulatory submission this year.